Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.67 |
| ▸ | GSR | P00390 | 2/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.59 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.59 |
| ▸ | NOS1 | P29475 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ARG1 | P05089 | 3/20 | 0.54 |
| ▸ | ARG2 | P78540 | 3/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norleucine SCHEMBL8393 | 1.00 | — | — | |
| Norleucine SCHEMBL8392 | 1.00 | — | — | |
| Norleucine SCHEMBL198127 | 1.00 | — | — | |
| Norleucine SCHEMBL5051846 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL2785913 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL5497693 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL4608461 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL13736626 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL4163267 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL15051960 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1520073-B1 | TRIAZINNYLAMINOSTILBENE DISULPHONIC ACID MIXTURES | BASF SE (DE) | 2012-01-18 | — | — | EP | claimed |
| EP-2292837-A1 | Triazinylaminostilbene disulphonic acid mixtures | BASF SE (DE) | 2011-03-09 | — | — | EP | claimed |
| US-7585333-B2 | Fluorescent whitening agent, for whitening synthetic or natural organic materials, especially paper and for the fluorescent whitening and improvement of sun protection factors of textile materials | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2009-09-08 | — | — | US | claimed |
| US-20080307585-A1 | Fluorescent whitening agent, for whitening synthetic or natural organic materials, especially paper and for the fluorescent whitening and improvement of sun protection factors of textile materials | CIBA SPECIALTY CHEMICALS CORP. | 2008-12-18 | — | — | US | claimed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| US-8124357-B2 | Cell comprising exogenous clostridial toxin receptor for use as quality control agents in pharmaceutical and food processing | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2417981-A1 | Peptide PTTKTYFPHF and its uses | CMS Peptides Patent Holding Company Limited (VG) | 2012-02-15 | — | — | EP | disclosed |
| EP-1520073-B1 | TRIAZINNYLAMINOSTILBENE DISULPHONIC ACID MIXTURES | BASF SE (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-1438586-B1 | FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS | ALLERGAN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1901069-B1 | Fret protease assays for clostridial toxins | ALLERGAN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8067231-B2 | Clostridial toxin activity assays | ALLERGAN, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8053209-B2 | FRET protease assays for clostridial toxins | ALLERGAN, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8013113-B2 | FRET protease assays for clostridial toxins | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8003753-B2 | Fret protease assays for clostridial toxins | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2154151-B1 | Clostridial toxin activatable clostridial toxins | ALLERGAN INC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110111479-A1 | Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs | ALLERGAN, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2316035-A2 | THROMBIN SUBSTRATE AND ASSAY FOR DETERMINING THE LEVEL OF BIOACTIVE THROMBIN IN A SAMPLE | Radiometer Medical ApS (DK) | 2011-05-04 | — | — | EP | disclosed |
| EP-2292837-A1 | Triazinylaminostilbene disulphonic acid mixtures | BASF SE (DE) | 2011-03-09 | — | — | EP | disclosed |
| CN-101501062-A | Novel biologically active peptides and their new uses | CMS MEDICAL SYSTEM HOLDING SHE (CN) | 2009-08-05 | — | — | CN | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | SLC1A2 544/4885SLC1A1 937/4885SLC1A3 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.